74436-00-3
Chemical Structure
Cyclosporin G
- CAS No.: 74436-00-3
- Formula:C63H113N11O12
- Molecular Weight:1216.64
IUPAC Name: (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
InChIKey: ZMKGDQSIRSGUDJ-VSROPUKISA-N
SMILES: C/C=C/C[C@@H](C)[C@H]([C@]1([H])N(C([C@@H](N(C([C@@H](N(C([C@@H](N(C([C@H](NC([C@@H](NC([C@@H](N(C([C@@H](NC([C@@H](N(C(CN(C([C@@H](NC1=O)CCC)=O)C)=O)C)CC(C)C)=O)C(C)C)=O)C)CC(C)C)=O)C)=O)C)=O)C)CC(C)C)=O)C)CC(C)C)=O)C)C(C)C)=O)C)O
Biological Activity: Cyclosporin G is a cyclic peptide analog of Cyclosporin A (HY-B0579) metabolized by CYP3A4, and is an immunosuppressant. Cyclosporin G inhibits interleukin-1β-induced NO synthase expression/nitrite production and inhibits insulin release from isolated human pancreatic islets. Cyclosporin G is cytotoxic to hepatoblastoma cells and induces intracellular calcium elevation and necrosis. Cyclosporin G inhibits P-glycoprotein-mediated dye efflux. Cyclosporin G can be used in research on psoriasis and multiple myeloma[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cyclosporin G | 95.0% | Cyclosporin G is a cyclic peptide analog of Cyclosporin A (HY-B0579) metabolized by CYP3A4, and is an immunosuppressant. Cyclosporin G inhibits interleukin-1β-induced NO synthase expression/nitrite production and inhibits insulin release from isolated human pancreatic islets. Cyclosporin G is cytotoxic to hepatoblastoma cells and induces intracellular calcium elevation and necrosis. Cyclosporin G inhibits P-glycoprotein-mediated dye efflux. Cyclosporin G can be used in research on psoriasis and multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Burdmann EA, et al. Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney international. 1994 Mar;45(3):684-91. [Content Brief]
- [2]. Ellouk-Achard S, et al. Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture. Archives of toxicology. 1997 May;71(7):437-42.
- [3]. Mühl H, et al. Cyclosporin derivatives inhibit interleukin 1 beta induction of nitric oxide synthase in renal mesangial cells. European journal of pharmacology. 1993 Nov 02;249(1):95-100.
- [4]. Teofoli P, et al. Cyclosporin G inhibits proliferation of A431 cells in a dose- and time-dependent manner comparable to cyclosporin A. Skin pharmacology : the official journal of the Skin Pharmacology Society. 1997;10(2):79-84. [Content Brief]
- [5]. Pilarski LM, et al. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Leukemia. 1998 Apr;12(4):505-9.
- [6]. Nielsen JH, et al. Direct effects of cyclosporin A on human pancreatic β-cells. Diabetes. 1986 Sep 1;35(9):1049-52. [Content Brief]
